Week of September 7th 2021 | Vol. 10, Issue 37
In This Issue
Featured Headlines
Recent Industry Transactions
Industry Trading Comps
Recent Industry Headlines
Market Reports
Upcoming Events

Quick Links

Contact Information
Managing Director
Business Development

Managing Director
Head of M&A and Capital Advisory

Above is an overview of recent industry M&A activity. For additional information, see the charts below or click on the chart above to download complete transaction tables broken out by industry sub sectors.

For more information about our consumer healthcare JV with The Emerson Group, Daybreak Consumer Care, click here.
Recent Materials Providing Insight Into Healthcare Related Industries
Current M&A Pipeline
Representative Current Retained Sell-Side And Partnering Opportunities
Project Power Play
Buy-side | Specialty Pharma | In-license and acquire approved Rx products including legacy brands, generics, and niche launch-ready products

Project Alamo
Sell-side | CMO | Corporate Carve out - private label and OTC manufacturing business

Project Focus
Sell-side | CMO | Liquids and Semi-solids CMO headquartered in North America

Project Trident
Buy-side | Generic Pharma | Manufacturing liquid generics

Project Aspen
Sell-side | CDMO | Multinational CDMO headquartered in US

Project Athena
Sell-side / Licensing | Medical Device | Novel device for pelvic organ prolapse
Our partner Aprecia, Purdue University, and the US Pharmacopeia are launching a webinar series on Pharmaceutical 3D Printing Technology. The 10-part series will explore the benefits this technology to patients with novel delivery forms and product capabilities while also providing product differentiation and IP protection for pharmaceutical companies seeking innovation for their oral drug products and product candidates from early development through commercial manufacturing.
There is no cost to attend and the webinar will be recorded for future viewing for registered attendees if the times are not conducive to their schedule at the time of airing. For more information and to register for the first three sessions that have been announced, click the link below.
An Overview of Transactions Within Market Sub-segments
Below are summaries and charts with the past week's transactions from the different healthcare sectors. For a detailed table showing data for each industry transaction click on any of the charts. Total transaction values are provided in USD millions.
Pharma & Biotech
7 transactions totaling $4,219 million
Supplies, Equipment & Services
9 transactions totaling $455 million
Healthcare IT & Managed Care
4 transactions totaling $9 million
Healthcare Facilities & Distributors
5 transactions totaling $290 million
Pharma & Biotech
27 transactions totaling $1,137 million
Supplies, Equipment & Services
16 transactions totaling $641 million
Healthcare IT & Managed Care
10 transactions totaling $155 million
Healthcare Facilities & Distributors
2 transactions totaling $1 million
Pharma & Biotech
12 transactions totaling $2,673 million
Supplies, Equipment & Services
15 transactions totaling $4,250 million
Healthcare IT & Managed Care
2 transaction totaling $2 million
Healthcare Facilities & Distributors
0 transactions
A Breakdown of Relevant Trading Multiples
Each week, we provide updated trading comps for leading companies from numerous healthcare sub-sectors.
To the right you will see a high-level breakdown of median revenue and EBITDA multiples for each of the specific sub sectors.

For a complete trading comp analysis (including the individual equities that comprise the sub sectors), click on the table. 

Note: data reflects prior week close.
A Sampling of Relevant Industry Headlines from Last Week
Below are snippets from relevant industry news articles from the past week. For additional information or the article's complete text, click the headline link to view the original publication.
September 7, 2021 - Fierce Healthcare
Cityblock Health's model to disrupt primary care appears to be resonating with investors in a big way. The startup, a healthcare provider focused on marginalized populations with complex needs, raised $400 million in a late-stage funding round that brings the company’s valuation to $5.7 billion, Stat reported Friday, citing sources familiar with the matter. The round was led by SoftBank, Stat's Erin Brodwin reported.

September 8, 2021 - Fierce Pharma
Sanofi has yet to wrap up its $3.2 billion acquisition of mRNA specialist Translate Bio, but the French pharma is already reaching out to its wallet. This time, it’s making a play in general medicines. In a surprising move, Sanofi is paying $1.9 billion in cash to scoop up U.S. biotech Kadmon, the companies said Wednesday. The deal gives Sanofi access to Rezurock less than two months after the drug snagged a first-in-class FDA nod to treat chronic graft-versus-host disease (cGVHD) after two prior therapies.

September 8, 2021 - Fierce Healthcare
Medical genetic company Invitae will acquire consumer health technology company Ciitizen for $325 million in a bid to make it easier for patients to collect their genomic and clinical information. Ciitizen, a company backed by several investors including 16z, Section 32 and Verily, is focused on building a global platform to help patients collect, organize, store and share their medical records digitally. Invitae is working to aggregate results from the world's genetic tests into a single, easy-to-use service that makes genetic information accessible to all who can benefit from it. 

September 9, 2021 - Fierce Healthcare
Pediatric teletherapy provider DotCom Therapy closed its series A funding, securing $13 million, the Madison, Wisconsin-based startup announced Thursday. New Capital Partners led the funding round with participation from LRVHealth and OSF Ventures. Along with the new capital, three executives will join DotCom Therapy’s board of directors: Will Cowen, general partner of LRVHealth, Stan Lynall, vice president of investments for OSF Ventures and James Outland, managing partner of New Capital Partners.
Events Hosted or Attended by Bourne Partners

September 14, 2021 - Virtual Webinar

November 9-11, 2021 - Milan, Italy

January 10-14, 2022 - San Francisco, CA
Welcome to Bourne, let's talk.

Since our founding in 2001, Bourne Partners has remained focused on fulfilling the unique needs of established, middle-market healthcare and pharmaceutical companies across the globe. Our track record includes advising middle market companies in healthcare M&A assignments totaling more than $7 billion, and growing companies into successful and well-positioned pharmaceutical enterprises.